Pfizer said that it was acquiring the rights to a new experimental substance aimed to help Alzheimer's disease. The substance (Pictured Above) is Dimebolin, a antihistamine that works on the AMPA/NMDA receptors. It has show positive results in Russia for Mild/Moderate stage patients of Alzheimer's disease by inhibiting brain cell death in preclinical studies of Alzheimer's. Pfizer has caught on to this new experimental pharmaceutical and is wishing to aquire a license on it. Pfizer will assume 60 percent of the development costs and take in 60 percent of the profits. I believe that Pfizer is more concerned with these experimental substances not to help those with Alzheimer's or other forms of dementia but from a buisiness standpoint. As John Locke said everyone should have their own human rights. I think if a drug like this exists in the world then it should be readily available and something like "aquiring the rights" or finding out the percent of profit the company will make should be irrelevant.
New York Times
Original Article
No comments:
Post a Comment